Metformin Combining PD-1 Inhibitor Enhanced Anti-Tumor Efficacy in STK11 Mutant Lung Cancer Through AXIN-1-Dependent Inhibition of STING Ubiquitination

Background: Non-small-cell lung cancer (NSCLC) with STK11 mutation showed primary resistance to immune checkpoint inhibitors (ICIs). The glucose-lowering drug metformin exerted anti-cancer effect and enhanced efficacy of chemotherapy in NSCLC with KRAS/STK11 co-mutation, yet it is unknown whether me...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhiguo, Lu, Conghua, Zhang, Kejun, Lin, Caiyu, Wu, Fang, Tang, Xiaolin, Wu, Di, Dou, Yuanyao, Han, Rui, Wang, Yubo, Hou, Chao, Ouyang, Qin, Feng, Mingxia, He, Yong, Li, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Molecular Biosciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905189/
https://www.ncbi.nlm.nih.gov/pubmed/35281267
http://dx.doi.org/10.3389/fmolb.2022.780200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905189/
https://www.ncbi.nlm.nih.gov/pubmed/35281267
http://dx.doi.org/10.3389/fmolb.2022.780200

Ejemplares similares